NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
Clinical Trials
15 trialsNCT03798626 2026-01-27
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04804813 2025-04-11
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Takeda
Completed
NCT00940225 2024-04-25
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Phase 2 Completed
NCT04540705 2024-02-28
PIVOT IO 011
Bristol-Myers Squibb
Phase 1 Completed
NCT03428217 2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT04353765 2021-11-17
US NIS Cabo
Ipsen
Completed
NCT01908426 2021-05-06
CELESTIAL
Exelixis
Phase 3 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT04637204 2021-02-01
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
Ipsen
Completed
NCT01605227 2018-03-14
COMET-1
Exelixis
Phase 3 Completed
NCT01553656 2015-08-20
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Exelixis
Phase 1 Completed
NCT01018745 2011-01-07
Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
Bristol-Myers Squibb
Phase 1 Completed